PURPOSE: Few interventions have been designed and tested to improve recruitment to clinical trials in oncology. The multiple factors influencing patients' decisions have made the prioritization of specific interventions challenging. The present study was undertaken to identify the independent predictors of a cancer patient's decision to enter a randomized clinical trial. METHODS: A list of factors from the medical literature was augmented with a series of focus groups involving cancer patients, physicians, and clinical research associates (CRAs). A series of questionnaires was developed with items based on these factors and were administered concurrently to 189 cancer patients, their physicians, and CRAs following the patient's decision regarding trial entry. Forward logistic regression modeling was performed using the items significantly correlated (by univariate analysis) with the decision to enter a clinical trial. RESULTS: A number of items were significantly correlated with the patient's decision. In the multivariate logistic regression model, the patient's perception of personal benefit was the most important, with an odds ratio (OR) of 3.08 (P < .05). CRA-related items involving supportive aspects of the decision-making process were also important. These included whether the CRA helped with the decision (OR = 1.71; P < .05), and whether the decision was hard for the patient to make (OR = 0.52; P < .05). CONCLUSION: Strategies that better address the potential benefits of trial entry may result in improved accrual. Interventions or aids that focus on the supportive aspects of the decision-making process while respecting the need for information and patient autonomy may also lead to meaningful improvements in accrual.
RCT Entities:
PURPOSE: Few interventions have been designed and tested to improve recruitment to clinical trials in oncology. The multiple factors influencing patients' decisions have made the prioritization of specific interventions challenging. The present study was undertaken to identify the independent predictors of a cancerpatient's decision to enter a randomized clinical trial. METHODS: A list of factors from the medical literature was augmented with a series of focus groups involving cancerpatients, physicians, and clinical research associates (CRAs). A series of questionnaires was developed with items based on these factors and were administered concurrently to 189 cancerpatients, their physicians, and CRAs following the patient's decision regarding trial entry. Forward logistic regression modeling was performed using the items significantly correlated (by univariate analysis) with the decision to enter a clinical trial. RESULTS: A number of items were significantly correlated with the patient's decision. In the multivariate logistic regression model, the patient's perception of personal benefit was the most important, with an odds ratio (OR) of 3.08 (P < .05). CRA-related items involving supportive aspects of the decision-making process were also important. These included whether the CRA helped with the decision (OR = 1.71; P < .05), and whether the decision was hard for the patient to make (OR = 0.52; P < .05). CONCLUSION: Strategies that better address the potential benefits of trial entry may result in improved accrual. Interventions or aids that focus on the supportive aspects of the decision-making process while respecting the need for information and patient autonomy may also lead to meaningful improvements in accrual.
Authors: Russell K Schutt; Lidia Schapira; Jennifer Maniates; Jessica Santiccioli; Silas Henlon; Judyann Bigby Journal: J Community Health Date: 2010-08
Authors: Gwendolyn P Quinn; Alexis Koskan; Kristen J Wells; Luis E Gonzalez; Cathy D Meade; Christie L Pratt Pozo; Paul B Jacobsen Journal: J Cancer Educ Date: 2012-06 Impact factor: 2.037
Authors: Taher Abu-Hejleh; Elizabeth A Chrischilles; Thorvardur R Halfdanarson; Christian Simon; Jane F Pendergast; Dingfeng Jiang; Carmen J Smith; Aaron T Porter; Knute D Carter; Robert B Wallace Journal: Am J Clin Oncol Date: 2016-04 Impact factor: 2.339
Authors: S Manne; D Kashy; T Albrecht; Y-N Wong; A Lederman Flamm; A B Benson; S M Miller; Linda Fleisher; J Buzaglo; N Roach; M Katz; E Ross; M Collins; D Poole; S Raivitch; D M Miller; T G Kinzy; T Liu; N J Meropol Journal: Eur J Cancer Care (Engl) Date: 2014-01-28 Impact factor: 2.520